SCHEMBL23668196

SCHEMBL23668196

Cc1ccc(S(=O)(=O)n2ccc3ccnc(Cl)c32)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.56
▸ TUBB4A P04350 1/20 0.46
▸ TUBB P07437 1/20 0.46
▸ TUBA3C P0DPH7 1/20 0.46
▸ TUBA1B P68363 1/20 0.46
▸ TUBA4A P68366 1/20 0.46
▸ TUBB4B P68371 1/20 0.46
▸ TUBB3 Q13509 1/20 0.46
▸ TUBB2A Q13885 1/20 0.46
▸ TUBB8 Q3ZCM7 1/20 0.46
▸ TUBA3E Q6PEY2 1/20 0.46
▸ TUBA1A Q71U36 1/20 0.46
▸ TUBA1C Q9BQE3 1/20 0.46
▸ TUBB6 Q9BUF5 1/20 0.46
▸ TUBB2B Q9BVA1 1/20 0.46
▸ TUBB1 Q9H4B7 1/20 0.46
▸ PKM P14618 1/20 0.46
▸ BRD4 O60885 1/20 0.43
▸ HTT P42858 2/20 0.42
▸ POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14059915 0.86 CYP2C19 (0.55) L3MBTL1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL26623444 0.81 L3MBTL1 (0.53) L3MBTL1TUBB4ATUBBTUBA3CTUBA1B
SCHEMBL30743470 0.78 L3MBTL1 (0.49) L3MBTL1PKMBRD4HTTPOLB
SCHEMBL20505742 0.78 L3MBTL1 (0.46) L3MBTL1PKMBRD4HTTPOLB
SCHEMBL31409625 0.78 L3MBTL1 (0.49) L3MBTL1PKMHTTPOLBALDH3A1
SCHEMBL4449281 0.77 L3MBTL1 (0.55) L3MBTL1PKMBRD4HTTPOLB
SCHEMBL26912671 0.77 L3MBTL1 (0.48) L3MBTL1PKMBRD4HTTPOLB
SCHEMBL2241322 0.75 L3MBTL1 (0.46) L3MBTL1PKMBRD4HTTPOLB
SCHEMBL30810137 0.75 L3MBTL1 (0.42) L3MBTL1PKMBRD4HTTPOLB
SCHEMBL23668176 0.75 L3MBTL1 (0.42) L3MBTL1PKMBRD4HTTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12234232-B2 Aromatic heterocyclic compound with kinase inhibitory activity SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) 2025-02-25 — — US disclosed
US-20210371415-A1 AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) 2021-12-02 — — US disclosed
EP-3854793-A1 AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) 2021-07-28 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210371415-A1 AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY JAK1, JAK2, JAK3 L3MBTL1 3281/4885TUBB4A 3583/4885TUBB 3237/4885
US-12234232-B2 Aromatic heterocyclic compound with kinase inhibitory activity JAK1, JAK2, JAK3 L3MBTL1 3281/4885TUBB4A 3583/4885TUBB 3237/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback